Sorry if this has already been posted:
Nortran Pharmaceuticals Inc - In the News
Maedel says he may sell Nortran soon
Nortran Pharmaceuticals Inc NRT
Shares issued 27,673,299 May 27 close $1.42
Thu 27 May 99 In the News
Neil Maedel, writing in the May 27, 1999 edition of Maedel's Mini-Cap
Analyst, says Nortran Pharmaceuticals may be close to closing a major
licensing deal with Hoffman-La Roche. Since announcing the initial
collaboration with the company a year ago, Nortran stock has languished,
but the Swiss-based newsletter writer says it should again surpass the $2
mark "and might retest its old highs, a point where profit-taking will
likely be prudent." Mr. Maedel warns, however, that there is a caveat in
the profit-taking decision: Nortran's promising cough compound will enter
the clinic by June 15 and results are expected by the end of August: in
other words, not a long window. Nortran has other drug development programs
and prospective deals moving forward, which distinguishes it from
competitors like Inflazyme Pharmaceuticals. "If we sell, it will be no more
than half of our position," Mr. Maedel concludes.
(c) Copyright 1999 Canjex Publishing Ltd. canada-stockwatch.com |
